Evidence map›Paper›PMID 42639747›Full record

ArticleStatistics in medicine2026

Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models.

Lukas Owens, Dimitris Rizopoulos, Jonathan Fainberg, Sigrid Carlsson, Nicole Liso, Sean McBride, Vincent Laudone, Ruth Etzioni, Jeremy M G Taylor

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lukas OwensDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-5149-5379
Dimitris RizopoulosDepartment of Biostatistics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0001-9397-0900
Jonathan FainbergDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sigrid CarlssonDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-3553-5710
Nicole LisoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sean McBrideDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Vincent LaudoneDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ruth EtzioniDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jeremy M G TaylorDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Modeling Precision Interventions for Prostate Cancer ControlU01CA253915 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, TSODIKOV, ALEXANDER · 2020 to 2025
$6.5M
Modeling and analytics for cancer diagnostics: traversing the data-evidence divideR35CA274442 · NCI · FRED HUTCHINSON CANCER CENTER · PI RUTH D ETZIONI · 2022 to 2026
$4.9M
NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA274442NCI NIH HHS U01 CA253915
6 · The paper itself

Abstract

Prostate cancer patients with biochemical recurrence (BCR) face a decision of whether to start salvage therapy (ST), which may reduce the probability of metastatic progression at the cost of side effects. To inform the decision to start ST at or after BCR, models that make counterfactual predictions incorporating treatment are highly desirable. However, estimation of such models using observational data requires care due to time-varying confounding by the longitudinal biomarker prostate-specific antigen (PSA). Moreover, a careful definition of the estimands of interest, referred to as "predictimands", is required due to the possibility of delayed initiation of treatment after biochemical recurrence. In this study, we utilize the framework of joint longitudinal and survival models to tackle these issues, estimating a model for pre-ST PSA trajectories and risk of metastasis that incorporates the effect of ST, from a dataset of 2075 patients with BCR. We define relevant predictimands for a new patient after BCR under three scenarios: Immediately treated, never treated, and treatment under a dynamic regime, where ST is started when PSA is observed to exceed a pre-specified threshold. We propose a Monte Carlo scheme for computing these predictimands, adapting previous work on dynamic predictions from joint models to account for treatment timing. This methodology is applied to an example patient and validated in a simulation study. This methodology could be adapted to a wide variety of applications requiring counterfactual predictions in the presence of time-varying treatments and biomarkers. Code to implement such analyses is available in the R package JMbayes2.

Indexed as

Models, StatisticalNeoplasm Recurrence, LocalProstatic NeoplasmsSalvage TherapyBiomarkers, TumorComputer SimulationHumansLongitudinal StudiesMaleMonte Carlo MethodPrediction AlgorithmsProstate-Specific AntigenSurvival AnalysisBiomarkers, TumorProstate-Specific Antigencausal inferencedynamic predictionsjoint modelslongitudinal datapredictive modelssurvival analysis

Identifiers

PMID42639747
PMCPMC13504709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.